[TABLE OF CONTENT]

1 INTRODUCTION OF GLOBAL GENE AMPLIFICATION TECHNOLOGY MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY: GENE AMPLIFICATION TECHNOLOGY MARKET

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS

4 GLOBAL GENE AMPLIFICATION TECHNOLOGY MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE

5 GLOBAL GENE AMPLIFICATION TECHNOLOGY MARKET, BY TECHNOLOGY
5.1 OVERVIEW
5.2 PCR-BASED AMPLIFICATION
5.3 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION
5.4 NUCLEIC ACID SEQUENCE BASED AMPLIFICATION
5.5 STRAND DISPLACEMENT AMPLIFICATION
5.6 MULTIPLE DISPLACEMENT AMPLIFICATION
5.7 ROLLING CIRCLE AMPLIFICATION
5.8 RAMIFICATION AMPLIFICATION
5.9 OTHERS

6 GLOBAL GENE AMPLIFICATION TECHNOLOGY MARKET, BY DOWNSTREAM
6.1 OVERVIEW
6.2 WHOLE GENOME AMPLIFICATION
6.3 EXOME SEQUENCING
6.4 SNP GENOTYPING ARRAYS
6.5 ARRAY CGH
6.6 HYBRIDIZATION
6.7 OTHERS

7 GLOBAL GENE AMPLIFICATION TECHNOLOGY MARKET, BY SAMPLE TYPE
7.1 OVERVIEW
7.2 SINGLE-CELL
7.3 FORMALIN-FIXED PARAFFIN-EMBEDDED
7.4 OTHERS

8 GLOBAL GENE AMPLIFICATION TECHNOLOGY MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 DEVICE
8.3 KITS AND REAGENTS
8.4 SERVICE

9 GLOBAL GENE AMPLIFICATION TECHNOLOGY MARKET, BY END-USERS
9.1 OVERVIEW
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.3 ACADEMIC & RESEARCH INSTITUTES
9.4 OTHERS 

10 GLOBAL GENE AMPLIFICATION TECHNOLOGY MARKET, BY GEOGRAPHY
10.1 OVERVIEW

10.2 NORTH AMERICA

10.2.1 NORTH AMERICA MARKET SNAPSHOT
10.2.2 U.S.
10.2.3 CANADA
10.2.4 MEXICO

10.3 EUROPE

10.3.1 EUROPE MARKET SNAPSHOT
10.3.2 WESTERN EUROPE
10.3.2.1 THE UK
10.3.2.2 GERMANY
10.3.2.3 FRANCE
10.3.2.4 ITALY
10.3.2.5 SPAIN
10.3.2.6 REST OF WESTERN EUROPE
10.3.3 EASTERN EUROPE
10.3.3.1 POLAND
10.3.3.2 RUSSIA
10.3.3.3 REST OF EASTERN EUROPE

10.4 ASIA PACIFIC

10.4.1 ASIA PACIFIC MARKET SNAPSHOT
10.4.2 CHINA
10.4.3 JAPAN
10.4.4 INDIA
10.4.5 AUSTRALIA & NEW ZEALAND
10.4.6 ASEAN
10.4.7 REST OF ASIA PACIFIC

10.5 MIDDLE EAST & AFRICA

10.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
10.5.2 UAE
10.5.3 SAUDI ARABIA
10.5.4 SOUTH AFRICA
10.5.5 REST OF MEA

10.6 SOUTH AMERICA

10.6.1 SOUTH AMERICA MARKET SNAPSHOT
10.6.2 BRAZIL
10.6.3 ARGENTINA
10.6.4 REST OF SOUTH AMERICA

11 GLOBAL GENE AMPLIFICATION TECHNOLOGY MARKET COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPANY MARKET RANKING
11.3 KEY DEVELOPMENT STRATEGIES
11.4 COMPETITIVE DASHBOARD
11.5 PRODUCT MAPPING
11.6 TOP PLAYER POSITIONING, 2022
11.7 COMPETITIVE HEATMAP
11.8 TOP WINNING STRATEGIES

12 COMPANY PROFILES

12.1 4BASEBIO AG
12.1.1 OVERVIEW
12.1.2 FINANCIAL PERFORMANCE
12.1.3 PRODUCT OUTLOOK
12.1.4 KEY DEVELOPMENTS
12.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

12.2 BIO-RAD LABORATORIES
12.2.1 OVERVIEW
12.2.2 FINANCIAL PERFORMANCE
12.2.3 PRODUCT OUTLOOK
12.2.4 KEY DEVELOPMENTS
12.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

12.3 DANAHER CORPORATION
12.3.1 OVERVIEW
12.3.2 FINANCIAL PERFORMANCE
12.3.3 PRODUCT OUTLOOK
12.3.4 KEY DEVELOPMENTS
12.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

12.4 ILLUMINA INC.
12.4.1 OVERVIEW
12.4.2 FINANCIAL PERFORMANCE
12.4.3 PRODUCT OUTLOOK
12.4.4 KEY DEVELOPMENTS
12.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

12.5 LGC GROUP
12.5.1 OVERVIEW
12.5.2 FINANCIAL PERFORMANCE
12.5.3 PRODUCT OUTLOOK
12.5.4 KEY DEVELOPMENTS
12.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

12.6 MERCK KGAA
12.6.1 OVERVIEW
12.6.2 FINANCIAL PERFORMANCE
12.6.3 PRODUCT OUTLOOK
12.6.4 KEY DEVELOPMENTS
12.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

12.7 MYBIOSOURCE
12.7.1 OVERVIEW
12.7.2 FINANCIAL PERFORMANCE
12.7.3 PRODUCT OUTLOOK
12.7.4 KEY DEVELOPMENTS
12.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

12.8 NEW ENGLAND BIOLABS
12.8.1 OVERVIEW
12.8.2 FINANCIAL PERFORMANCE
12.8.3 PRODUCT OUTLOOK
12.8.4 KEY DEVELOPMENTS
12.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

12.9 PROMEGA CORPORATION
12.9.1 OVERVIEW
12.9.2 FINANCIAL PERFORMANCE
12.9.3 PRODUCT OUTLOOK
12.9.4 KEY DEVELOPMENTS
12.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.10 QIAGEN
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.11 SILICON BIOSYSTEMS
10.11.1 OVERVIEW
10.11.2 FINANCIAL PERFORMANCE
10.11.3 PRODUCT OUTLOOK
10.11.4 KEY DEVELOPMENTS
10.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.12 TAKARA BIO INC.
10.12.1 OVERVIEW
10.12.2 FINANCIAL PERFORMANCE
10.12.3 PRODUCT OUTLOOK
10.12.4 KEY DEVELOPMENTS
10.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.13 VAZYME BIOTECH CO. LTD.
10.13.1 OVERVIEW
10.13.2 FINANCIAL PERFORMANCE
10.13.3 PRODUCT OUTLOOK
10.13.4 KEY DEVELOPMENTS
10.13.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.14 YIKANG GENE
10.14.1 OVERVIEW
10.14.2 FINANCIAL PERFORMANCE
10.14.3 PRODUCT OUTLOOK
10.14.4 KEY DEVELOPMENTS
10.14.5 KEY STRATEGIC MOVES AND DEVELOPMENTS